Hims & Hers: GLP-1 Partnership Could Unlock Value

Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November ...
Scientific Research Publishing

Dairy Business Sustainability, Market Risk Management Resilience and Stability Strategies ()

The dairy business and industry in Oman grapples with complex challenges, from wavering milk prices and escalating input ...
Investor's Business Daily on MSN

Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook

Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.